Acamprosate calcium
Modify Date: 2024-01-03 13:03:43
Acamprosate calcium structure
|
Common Name | Acamprosate calcium | ||
|---|---|---|---|---|
| CAS Number | 77337-73-6 | Molecular Weight | 200.24 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C5H10NO4S.1/2Ca | Melting Point | >300ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of Acamprosate calciumAcamprosate calcium(Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems; reduces alcohol consumption in animal models of alcohol addiction.IC50 value:Target: GABA receptorAcamprosate, or N-acetyl homotaurine, is an N-methyl-D-aspartate receptor modulator approved by the Food and Drug Administration (FDA) as a pharmacological treatment for alcohol dependence.Acamprosate has low bioavailability, but also has an excellent tolerability and safety profile. In comparison with naltrexone and disulfiram, which are the other FDA-approved treatments for alcohol dependence, acamprosate is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so can be administered to patients with hepatitis or liver disease (a common comorbid condition among individuals with alcohol dependence) and to patients who continue drinking alcohol. |
| Name | acamprosate calcium |
|---|---|
| Synonym | More Synonyms |
| Description | Acamprosate calcium(Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems; reduces alcohol consumption in animal models of alcohol addiction.IC50 value:Target: GABA receptorAcamprosate, or N-acetyl homotaurine, is an N-methyl-D-aspartate receptor modulator approved by the Food and Drug Administration (FDA) as a pharmacological treatment for alcohol dependence.Acamprosate has low bioavailability, but also has an excellent tolerability and safety profile. In comparison with naltrexone and disulfiram, which are the other FDA-approved treatments for alcohol dependence, acamprosate is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so can be administered to patients with hepatitis or liver disease (a common comorbid condition among individuals with alcohol dependence) and to patients who continue drinking alcohol. |
|---|---|
| Related Catalog | |
| References |
| Melting Point | >300ºC |
|---|---|
| Molecular Formula | C5H10NO4S.1/2Ca |
| Molecular Weight | 200.24 |
| PSA | 189.36000 |
| LogP | 1.05900 |
| Storage condition | Room temp |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-36/37/39-36 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2924199090 |
| HS Code | 2924199090 |
|---|---|
| Summary | 2924199090. other acyclic amides (including acyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.
Sci. Rep. 5 , 7608, (2015) Alzheimer disease (AD) represents a major medical problem where mono-therapeutic interventions demonstrated only a limited efficacy so far. We explored the possibility of developing a combinational th... |
|
|
Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat.
Neuropsychopharmacology 39(11) , 2601-10, (2014) Since its discovery, the nociceptin/orphanin FQ (N/OFQ)-NOP receptor system has been extensively investigated as a promising target to treat alcoholism. Encouraging results obtained with the endogenou... |
|
|
Acamprosate calcium as augmentation therapy for anxiety disorders.
Ann. Pharmacother. 44 , 1930-2, (2010) Glutamate is a major excitatory neurotransmitter, while γ-aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter in the central nervous system. This GABA-glutamate imbalance is thought ... |
| Campral |
| Acamprosate calcium |
| MFCD00886588 |
| calcium acetylhomotaurinate |
| Calciumbis[3-(acetylamino)propan-1-sulfonat] |
| CA-Aota |
| Alcomed |
| 3-(Acetylamino)-1-propanesulfonic Acid Calcium Salt (2:1) |
| Sobriol |
| 1-Propanesulfonic acid, 3-(acetylamino)-, calcium salt (2:1) |
| Calcium bis(3-acetamido-1-propanesulfonate) |
| Calcium Bisacetyl Homotaurine |
| bis[3-(acétylamino)propane-1-sulfonate] de calcium |
| Aotal |
| calcium acetyl homotaurinate |
| calcium bis[3-(acetylamino)propane-1-sulfonate] |
| calcium,3-acetamidopropane-1-sulfonate |
| EINECS 278-665-3 |
| Calcium bis(3-acetamidopropane-1-sulfonate) |
| Acamprosate (calcium) |